Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy

COVID-19 vaccination leads to a less intense humoral response in patients with multiple myeloma (MM) compared with healthy individuals, whereas the SARS-CoV-2-specific immunity fades over time. The purpose of this study was to explore the kinetics of SARS-CoV-2 neutralizing antibodies (NAbs) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntanasis-Stathopoulos, Ioannis, Karalis, Vangelis, Gavriatopoulou, Maria, Malandrakis, Panagiotis, Sklirou, Aimilia D., Eleutherakis-Papaiakovou, Evangelos, Migkou, Magdalini, Roussou, Maria, Fotiou, Despina, Alexopoulos, Harry, Theodorakakou, Foteini, Kastritis, Efstathios, Iconomidou, Vassiliki A., Trougakos, Ioannis P., Dimopoulos, Meletios A., Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345642/
https://www.ncbi.nlm.nih.gov/pubmed/35928542
http://dx.doi.org/10.1097/HS9.0000000000000764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345642/
https://www.ncbi.nlm.nih.gov/pubmed/35928542
http://dx.doi.org/10.1097/HS9.0000000000000764

Ejemplares similares